Wave Life Sciences Studies Fourth Quarter and Full Yr 2021 Monetary Outcomes and Supplies Enterprise Replace

Wave Life Sciences USA, Inc.

Medical information from a number of novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD anticipated in 2022

GalNAc-AIMers restore therapeutically related ranges of AAT for lung safety and scale back liver-damaging aggregates in preclinical examine; IND enabling toxicology research anticipated to provoke in 3Q 2022

FY2021 year-end money whole of $150.6 million offering runway into 2Q 2023

Wave to host investor convention name and webcast at 8:30 a.m. ET at present

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines firm dedicated to delivering life-changing

Read More Read More

Epizyme Stories Fourth Quarter and Full 12 months 2021 Monetary Outcomes and Gives Enterprise Replace

TAZVERIK® (tazemetostat) Internet Product Income of $11.6 Million for 4Q 2021; $30.9 Million for FY 2021

$85 Million in Gross Proceeds Raised in January 2022 Public Providing, Mixed with Latest Expense Reductions Introduced Immediately, Extends Money Runway into 3Q 2023

Firm Engaged in International Begin-up Actions for SYMPHONY-1; Information Updates Anticipated Throughout Pipeline Applications in 2022

CAMBRIDGE, Mass., March 01, 2022–(BUSINESS WIRE)–Epizyme (Nasdaq: EPZM), a completely built-in, commercial-stage biopharmaceutical firm creating and delivering transformative therapies for most cancers towards novel epigenetic targets, right now reported fourth quarter and full yr 2021 monetary outcomes and supplied enterprise and portfolio updates.

Read More Read More

Vaxart Offers Enterprise Replace and Stories Fourth Quarter and Full Yr 2021 Monetary Outcomes

Vaxart, Inc.

Firm begins 2022 with a number of energetic packages with knowledge readouts anticipated this yr

Preliminary knowledge from COVID-19 Part II examine anticipated within the first half of 2022 and knowledge from a number of norovirus research additionally anticipated this yr

Ended 2021 with $182.7 million in money, money equivalents and marketable securities

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) issued its enterprise replace right this moment for the fourth quarter and full yr 2021, reporting ahead momentum for the Firm, together with its oral norovirus and COVID-19 vaccine candidates.

Read More Read More

Allogene Therapeutics Experiences Fourth Quarter and Full 12 months 2021 Monetary Outcomes and Offers Enterprise Replace

Allogene Therapeutics, Inc.

  • AlloCAR T™ Research Resumed and At the moment Enrolling Sufferers Following Removing of Medical Maintain in January 2022

  • Section 1 Information from the ALPHA Trials in Relapsed/Refractory (RR) Non-Hodgkin Lymphoma Offered at ASH 2021 Demonstrated Potential for an AlloCAR T Product to be a Secure and Sturdy Various to Autologous Cell Remedy in CAR T Naïve Sufferers

  • Section 1 Information Offered at ASH 2021 from the ALLO-715 UNIVERSAL Trial in R/R A number of Myeloma Demonstrated Potential for an Allogeneic Anti-BCMA CAR T to Obtain Responses Much like Accepted Autologous CAR T Remedy with Added Advantage of

Read More Read More

CRISPR Therapeutics Offers Enterprise Replace and Stories Fourth Quarter and Full 12 months 2021 Monetary Outcomes

CRISPR Therapeutics AG

– Greater than 70 sufferers have been dosed with CTX001™ throughout CLIMB-Thal-111 and CLIMB-SCD-121 to this point; enrollment full and regulatory submissions deliberate for late 2022-

-Initiated and started dosing sufferers within the pivotal trial of CTX110™, concentrating on CD19+ B-cell malignancies; extra knowledge anticipated to report in 2022-

-High-line knowledge anticipated to report in 1H2022 for ongoing CTX120™ and CTX130™ medical trials-

-First affected person dosed in Section 1 medical trial of VCTX210 for the therapy of sort 1 diabetes (T1D)-

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),

Read More Read More

Nicox Supplies Fourth Quarter 2021 Enterprise and Monetary Highlights

January 21, 2022 – launch at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), a world ophthalmology firm, supplied enterprise and monetary highlights for fourth quarter 2021 for Nicox SA and its subsidiaries (the “Nicox Group”) in addition to key anticipated value-inflection milestones immediately.

Fourth Quarter 2021 Monetary Highlights

As of December 31, 2021, the Nicox Group had money and money equivalents of €41.9 million as in contrast with €32.7 million at September 30, 2021 and €47.2 million at December 31, 2020. The Firm is financed till fourth quarter 2023, financing improvement of NCX 470 solely.

Read More Read More